Comparative analyses of eighteen rapid antigen tests and RT-PCR for COVID-19 quarantine and surveillance-based isolation
Wells CR, Pandey A, Moghadas SM, Singer BH, Krieger G, Heron RJL, Turner DE, Abshire JP, Phillips KM, Michael Donoghue A, Galvani AP, Townsend JP. Comparative analyses of eighteen rapid antigen tests and RT-PCR for COVID-19 quarantine and surveillance-based isolation. Communications Medicine 2022, 2: 84. PMID: 35822105, PMCID: PMC9271059, DOI: 10.1038/s43856-022-00147-y.Peer-Reviewed Original ResearchRT-PCR testingRT-PCR testAntigen testRA testRT-PCRSerial testingSingle RT-PCR testSARS-CoV-2 infectionRapid antigen testEmergency use authorizationUnited States FoodExtent of transmissionDrug AdministrationCOVID-19 infectiousnessEffective reproduction numberStates FoodCOVID-19 quarantineQuarantine durationTest specificitySpread of diseaseDiagnostic characteristicsTesting strategiesReproduction numberFalse positive rateQuarantineSeasonality of endemic COVID-19
Townsend J, Hassler H, Lamb A, Sah P, Nishio A, Nguyen C, Tew A, Galvani A, Dornburg A. Seasonality of endemic COVID-19. MBio 2023, 14: e01426-23. PMID: 37937979, PMCID: PMC10746271, DOI: 10.1128/mbio.01426-23.Peer-Reviewed Original ResearchPublic health interventionsSARS-CoV-2Health interventionsSARS-CoV-2 infectionCOVID-19SARS-CoV-2 circulationEffective public health policiesLocal public health effortsEndemic COVID-19Public health effortsPublic healthPublic health policyLong-term dataCOVID-19 transmissionHealth effortsMedical preparednessVaccination driveHealth policyVaried interventionsEndemic diseaseSeasonal surgesInterventionInfectionEffective healthcareEndemic pathogensInfection with alternate frequencies of SARS-CoV-2 vaccine boosting for patients undergoing antineoplastic cancer treatments
Townsend J, Hassler H, Emu B, Dornburg A. Infection with alternate frequencies of SARS-CoV-2 vaccine boosting for patients undergoing antineoplastic cancer treatments. Journal Of The National Cancer Institute 2023, 115: 1626-1628. PMID: 37599438, PMCID: PMC10699797, DOI: 10.1093/jnci/djad158.Peer-Reviewed Original ResearchConceptsReinfection riskAntineoplastic therapyAntibody dataSARS-CoV-2 infectionSARS-CoV-2 vaccinesChemotherapy-immunotherapy combinationsPfizer-BioNTech BNT162b2COVID-19 vaccinationHigh infection riskFrequent boostingRituximab therapyBreakthrough infectionsVaccination scheduleAntibody levelsBooster scheduleVaccination frequencyImmune responseAdditional interventionsReduced riskHigh riskHormonal treatmentGeneral populationNecessitating assessmentPatientsInfection risk